Previous close | 2.9600 |
Open | 3.0000 |
Bid | 3.1800 x 29200 |
Ask | 3.2200 x 21500 |
Day's range | 2.9600 - 3.2250 |
52-week range | 2.0900 - 15.8640 |
Volume | |
Avg. volume | 21,971,730 |
Market cap | 5.703B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.6720 |
Earnings date | 16 May 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 8.43 |
The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...
SOUTH SAN FRANCISCO, Calif. & BOSTON, April 05, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a new supply agreement expanding the depth and breadth of the collaboration between two of the leading organizations in the synthetic biology ecosystem. The four-year agreement in
BRISBANE, Australia & BOSTON, April 04, 2022--Microba Life Sciences (ASX: MAP), a precision microbiome science company, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a partnership to identify single-strain, live bacteria product (LBP) candidates against autoimmune diseases. The collaboration aims to build on Microba’s precision approach to LBP development with an in-depth evaluation of the company’s strains using Ginkgo's high throughput,